The trial will continue until 691 confirmed primary outcome events have occurred , providing a power of 90 % to yield an upper limit of the adjusted 95 % CI for a hazard ratio of < 1.3 with a one-sided of 0.025 , assuming equal risks between placebo and empagliflozin ( both doses pooled ) .